1. Real-world trials to answer real-world questions

   • Nick Freemantle
   • Lawrence Blonde
   • Stuart Ross

   Practical Application 17 September 2012 Pages: 747 - 754

2. Pharmaceutical policy regarding generic drugs in Belgium

   • Steven Simoens
   • Kristien De Bruyn
   • Gert Laekeman

   Review Article 17 September 2012 Pages: 755 - 766

   

3. Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer

   • Elizabeth A. Calhoun
   • Glen T. Schumock
   • Charles L. Bennett

   Review Article 17 September 2012 Pages: 767 - 775

   

4. Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK

   • Louis S. Matza
   • Kristina Secnik
   • F. Randy Sallee

   Original Research Article 17 September 2012 Pages: 777 - 790

   

5. Societal discounting of health effects in cost-effectiveness analyses

   • Suzanne Polinder
   • Willem Jan Meerding
   • Werner Brouwer

   Original Research Article 17 September 2012 Pages: 791 - 802

   

6. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme

   • Janne A. Martikainen
   • Akseli Kivioja
   • Pia Vihinen

   Original Research Article 17 September 2012 Pages: 803 - 815

   

7. Cost of illness and its predictors for Parkinson’s disease in Germany

   • Annika E. Spottke
   • Martin Reuter
   • Richard Dodel

   Original Research Article 17 September 2012 Pages: 817 - 836

   

8. An economic evaluation of rizatriptan in the treatment of migraine

   • Melissa Thompson
   • Marek Gawel
   • Daniel Grima

   Original Research Article 17 September 2012 Pages: 837 - 850

   

9. Incorporation of uncertainty in health economic modelling studies

   • Mark Nuijten

   Correspondence 17 September 2012 Pages: 851 - 853

10. The authors’ reply

    • Anthony O’Hagan
    • Christopher McCabe
    • Andrew Willan

    Correspondence 17 September 2012 Pages: 853 - 853